论文部分内容阅读
目的探讨噻托溴铵与舒利迭吸入治疗老年D组慢性阻塞性肺疾病(COPD)的临床疗效。方法分析2013年6月至2014年6月期间48例D组COPD稳定期患者,随机分为2组,对照组应用舒利迭吸入,研究组应用噻托溴铵吸入,比较两组患者治疗2周及4周后的CAT评分、呼吸困难评分及肺功能指标。结果两组患者症状均有改善。与对照组比较,研究组疗效、呼吸困难评分及肺功能指标改善更佳(P<0.05)。结论噻托溴铵疗效优于舒利迭,更适合老年D组COPD患者,安全性好,医疗成本低。
Objective To investigate the clinical efficacy of tiotropium and seretide in the treatment of chronic obstructive pulmonary disease (COPD) in the elderly group. Methods Forty-eight patients with stable COPD in group D from June 2013 to June 2014 were randomly divided into two groups. The control group was treated with inhaled seretide. The study group was treated with tiotropium bromide. Patients in treatment group 2 Week and week 4 after the CAT score, dyspnea score and lung function indicators. Results The symptoms of both groups improved. Compared with the control group, the study group’s efficacy, dyspnea score and pulmonary function indicators improved better (P <0.05). Conclusion The efficacy of tiotropium bromide is better than that of seretide, which is more suitable for COPD patients of elderly group D. The safety is good and the medical cost is low.